WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Akeso lung cancer drug trial raises hopes in US$20b market — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 9 fonti

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Raccontata da

biopharmadive.com

fiercepharma.com

independent.co.uk

morningstar.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

scmp.comStai leggendo3 mesi fa

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Timeline cronologica

domenica 31 maggio 2026·biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…
domenica 31 maggio 2026·statnews.com
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

3 mesi fa

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.

Leggi questa versione → originale

statnews.com3 mesi fa

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso and Summit Therapeutics' ivonescimab reduced the risk of death by 34% in squamous non-small cell lung cancer patients versus standard treatment, in a Phase III trial published in The Lancet. For biotech and pharma-adjacent tech buyers, the result validates dual-mechanism oncology biologics and strengthens Summit's pipeline valuation ahead of potential ex-China regulatory filings.

Leggi questa versione → originale

fiercepharma.com3 mesi fa

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival…

Leggi questa versione → originale

biopharmadive.com3 mesi fa

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Leggi questa versione → originale

cnbc.com3 mesi fa

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

Akeso and Summit Therapeutics' bispecific antibody ivonescimab (PD-1/VEGF) reduced mortality risk by 34% in a Phase 3 China trial, extending median overall survival to 27.9 months vs. 23.7 months for standard PD-1 plus chemotherapy in squamous NSCLC. The data reignite the debate over whether PD-1/VEGF combos can succeed Keytruda ($30B+ in annual sales) as the standard-of-care backbone, though generalizability outside China remains unconfirmed until Harmoni-3 global results land in H2 2026.

Leggi questa versione → originale

domenica 31 maggio 2026·

fiercepharma.com

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t…

domenica 31 maggio 2026·

cnbc.com

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

domenica 31 maggio 2026·

endpoints.news

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard…

domenica 31 maggio 2026·

independent.co.uk

New drug a ‘promising step forward’ for hard-to-treat lung cancer

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer

domenica 31 maggio 2026·

morningstar.com

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to…

lunedì 1 giugno 2026·

scmp.com

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

lunedì 1 giugno 2026·

thenextweb.com

Akeso lung cancer drug cuts death risk 34% in landmark trial

Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.